Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease
- PMID: 813144
- DOI: 10.1056/NEJM197602192940805
Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease
Abstract
The clinical and biochemical abnormalities associated with Type 1 glycogen-storage disease can be reversed by avoidance of hypoglycemia and secondary hormonal flux. Three patients with Type 1 disease were treated with intragastric infusions of a high glucose formula at night with three-hour starch feedings during the day. This regimen stabilized blood glucose levels above 70 mg per deciliter and decreased serum uric acid, triglyceride, lactate and serum oxalacetic transaminase levels, as well as hepatic size, in all patients. Increased linear growth rate (mean 1 cm per month) was associated with a decrease in mean plasma glucagon (from 190 to 40 pg per milliliter) and an increase in mean plasma insulin (from 19 to 43 muU per milliliter, [two patients]). These changes occurred within four weeks of beginning of treatment and continued with home treatment for 13 months. No complications resulted from tube placement daily by the patients. Type 1 disease can be managed by nighttime intragastric feeding and frequent daytime high starch meals.
Similar articles
-
[Continuous nocturnal intragastric feeding in glycogenosis type I and III].Pediatrie. 1986 Apr-May;41(3):197-203. Pediatrie. 1986. PMID: 3095784 French.
-
ATP depletion, a possible role in the pathogenesis of hyperuricemia in glycogen storage disease type I.J Clin Invest. 1978 Aug;62(2):321-8. doi: 10.1172/JCI109132. J Clin Invest. 1978. PMID: 276529 Free PMC article.
-
Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.Eur J Pediatr. 1983 Apr;140(2):102-4. doi: 10.1007/BF00441652. Eur J Pediatr. 1983. PMID: 6411473
-
Nutritional therapy for glycogen storage diseases.J Pediatr Gastroenterol Nutr. 2008 Aug;47 Suppl 1:S15-21. doi: 10.1097/MPG.0b013e3181818ea5. J Pediatr Gastroenterol Nutr. 2008. PMID: 18667910 Review.
-
[Treatment of glycogen storage diseases].Padiatr Padol. 1991;26(1):19-24. Padiatr Padol. 1991. PMID: 1905390 Review. German.
Cited by
-
mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease.Nat Commun. 2021 May 25;12(1):3090. doi: 10.1038/s41467-021-23318-2. Nat Commun. 2021. PMID: 34035281 Free PMC article.
-
The Eck fistula in animals and humans.Curr Probl Surg. 1983 Nov;20(11):687-752. doi: 10.1016/s0011-3840(83)80010-0. Curr Probl Surg. 1983. PMID: 6357642 Free PMC article.
-
Necrotic foci, elevated chemokines and infiltrating neutrophils in the liver of glycogen storage disease type Ia.J Hepatol. 2008 Mar;48(3):479-85. doi: 10.1016/j.jhep.2007.11.014. Epub 2007 Dec 28. J Hepatol. 2008. PMID: 18191274 Free PMC article.
-
Recombinant AAV-directed gene therapy for type I glycogen storage diseases.Expert Opin Biol Ther. 2011 Aug;11(8):1011-24. doi: 10.1517/14712598.2011.578067. Epub 2011 Apr 20. Expert Opin Biol Ther. 2011. PMID: 21504389 Free PMC article. Review.
-
Glycogen storage disease type I: Genetic etiology, clinical manifestations, and conventional and gene therapies.Pediatr Discov. 2023;1(2):e3. doi: 10.1002/pdi3.3. Epub 2023 Jul 24. Pediatr Discov. 2023. PMID: 38370424 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources